

10/697,443

=> file caplus

FILE 'CAPLUS' ENTERED AT 10:55:23 ON 04 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Jan 2007 VOL 146 ISS 2

FILE LAST UPDATED: 3 Jan 2007 (20070103/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que

L1

STR



Structure attributes must be viewed using STN Express query preparation.

L3 285 SEA FILE=REGISTRY SSS FUL L1

L4 14 SEA FILE=CAPLUS L3

=> d l4 1-14 ibib abs hitstr

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:680977 CAPLUS

DOCUMENT NUMBER: 145:145559

TITLE: Heteroaromatic quinoline compounds as phosphodiesterase inhibitors, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Verhoest, Patrick Robert; Helal, Christopher John; Hoover, Dennis Jay; Humphrey, John Michael

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006072828	A2	20060713	WO 2005-IB3937	20051222
WO 2006072828	A3	20061109		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006154931 A1 20060713 US 2006-326221 20060105

NL 1030863 A1 20060710 NL 2006-1030863 20060106

PRIORITY APPLN. INFO.: US 2005-642058P P 20050107

OTHER SOURCE(S): MARPAT 145:145559

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to heteroaryl quinoline derivs. of formula I, which are phosphodiesterase (PDE) inhibitors, in some cases selective PDE-10 inhibitors. In compds. I, each R1 is independently selected from H, halo, OH, cyano, C1-8 alkyl, C2-8 alkenyl, C1-8 alkoxy, 4- to 7-membered heterocyclyl, etc.; p is 0-3; Het1 is (un)substituted mono- or bicyclic heteroaryl; Het2 is (un)substituted mono- or bicyclic heteroaryl, where Het2 is vicinal to the Ph ring on Het1; X1 and X2 are independently selected from O, S, (un)substituted N, and (un)substituted C, where at least one of X1 and X2 is C; and each Y is independently selected from N and (un)substituted C; provided that Het2 is not a tetrazole. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, as well as to the use of the compns. for the treatment of neurodegenerative and psychiatric disorders, such as psychosis. Substitution of 2-(chloromethyl)quinoline with Me 4-hydroxybenzoate followed by hydrolysis and amidation gave Weinreb amide II, which underwent addition of deprotonated 4-methylpyridine to give ketone III. Condensation of III with N-(dimethoxymethyl)-dimethylamine and heterocyclization with hydrazine gave pyrazole IV. The compds. of the invention express IC50 values for PDE-10 inhibition of less than 10  $\mu$ M (no specific data).

IT 898564-29-9P, 2-[[4-[2-(Pyridin-4-yl)ethynyl]phenoxy]methyl]quinoline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of heteroaryl quinoline compds. as PDE inhibitors)

RN 898564-29-9 CAPLUS

CN Quinoline, 2-[[4-(4-pyridinylethynyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



AB The invention is related to the preparation of fused heterocycles of formula I  
[A, B = independently N, S, O, a bond, etc.; D = C, N, S, O, C:C; U, V, W  
= independently CH and derivs., N; Y = a bond, CONH2 and derivs., SO,  
etc.; Z = H, halo, CN, etc.; X1 = a bond, halo, O, SO, NHSO2, etc.; R1 = a  
bond, (un)substituted benzofuranyl, benzimidazolyl, pyrrolyl, etc.; when  
R1 is not a bond, then X2 = a bond, O,S, NHCO and derivs., aliphatic group,  
etc.; or when R1 = a bond, then X2 = a bond and R2 is not a bond; R2 = a

10/697,443

bond or (un)substituted benzoxazolyl, Ph, etc.; with provisos; and with the exception of certain compds.], and their pharmaceutically acceptable salts as inhibitors of kinases, particularly COT or MK2 kinases. The invention is also related to the use of certain compds. I as inhibitors of angiogenic receptor tyrosine kinases. Thus, reacting 4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide with cyclopropanecarboxaldehyde gave thienopyridine II. All compds. I significantly inhibit either COT or MK2 at concns. of 50  $\mu$ M or below.


IT 870242-79-8P, 4-[[4-[(Pyridin-3-yl)ethynyl]phenoxy]thieno[2,3-c]pyridine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

RN 870242-79-8 CAPLUS

CN Thieno[2,3-c]pyridine-2-carboxamide, 4-[4-(3-pyridinyethynyl)phenoxy]-(9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1176932 CAPLUS

DOCUMENT NUMBER: 143:440271

TITLE: Preparation of alkynyl pyridine derivatives as MCH receptor antagonists

INVENTOR(S): Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald Juergen; Schindler, Marcus; Thomas, Leo; Lotz, Ralf R. H.; Rudolf, Klaus

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103032	A2	20051103	WO 2005-EP3686	20050408
WO 2005103032	A3	20060202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW



RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

DE 102004017930	A1	20051103	DE 2004-102004017930	20040414
CA 2558755	A1	20051103	CA 2005-2558755	20050408
EP 1737824	A2	20070103	EP 2005-732062	20050408

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

US 2005245529	A1	20051103	US 2005-105010	20050413
PRIORITY APPLN. INFO.:			DE 2004-102004017930A	20040414
			US 2004-563631P	P 20040420
			WO 2005-EP3686	W 20050408

OTHER SOURCE(S): MARPAT 143:440271  
 GI



II

AB Title compds. I [R1 and R2 independently = H, (un)substituted alkyl, cycloalkyl, etc. or R1 and R2 together form a (un)substituted alkylene bridge in which one CH<sub>2</sub> group not adjacent to NR<sub>1</sub>R<sub>2</sub> may be replaced by O, S, SO, etc.; X = (un)substituted alkylene bridge; W and Z independently = single bond or (un)substituted alkylene bridge in which two adjacent C-atoms may be connected to each other; Y and A independently = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; B = (un)substituted alkyl, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as MCH receptor antagonists. Thus, e.g., II was prepared by Sonogashira coupling of 3-(4-iodo-phenyl)cyclohexanol (preparation given) with 5-(4-chloro-phenyl)-2-ethynyl-pyridine followed by mesylation and subsequent coupling with 3,5-dimethylpiperidine. The binding activity of I towards MCH-1 receptor was evaluated using scintillation assay and it was revealed that selected compds. of the invention possessed IC<sub>50</sub> values in the range of 3.7 up to 25 nM. I as MCH receptor antagonist should prove useful in the treatment of diseases such as but not limited to bulimia, diabetes and obesity. Pharmaceutical compns. comprising I are disclosed.

IT 868608-73-5P 868608-75-7P 868608-78-0P  
 868608-81-5P 868608-82-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/697,443

(preparation of alkynyl pyridine derivs. as MCH receptor antagonists)

RN 868608-73-5 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-methyl-2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 868608-75-7 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2R)-2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868608-78-0 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2S)-2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868608-81-5 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2R)-3-methyl-2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868608-82-6 CAPLUS

10/697,443

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2S)-3-methyl-2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 868609-65-8P 868609-68-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of alkynyl pyridine derivs. as MCH receptor antagonists)

RN 868609-65-8 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(1R)-2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868609-68-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(1S)-2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:1155535 CAPLUS  
 DOCUMENT NUMBER: 143:422040  
 TITLE: Diarylalkyne compounds with MCH-receptor antagonistic activity, their preparation, pharmaceutical compositions, and use in therapy  
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany  
 SOURCE: U.S. Pat. Appl. Publ., 62 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239826	A1	20051027	US 2005-104915	20050413
DE 102004017935	A1	20051103	DE 2004-102004017935	20040414
CA 2559021	A1	20051103	CA 2005-2559021	20050408
WO 2005103031	A1	20051103	WO 2005-EP3683	20050408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2004-102004017935A 20040414  
 US 2004-563677P P 20040420  
 WO 2005-EP3683 W 20050408

OTHER SOURCE(S): MARPAT 143:422040  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to alkyne compds. of general formula I, which are antagonists of melanin-concentrating hormone (MCH) receptors. In compds. I, R1 is selected from C3-6 alkenyl, C3-6 alkynyl, (hydroxy-C3-7 cycloalkyl)-C1-3 alkyl, oxa-C4-7 cycloalkyl, and dihydroxy-C3-7 alkyl, each optionally substituted; R2 is independently selected from H, (un)substituted C1-8 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted pyridinyl, etc., or R1 and R2, together with the N atom to which they are bound, form an (un)substituted heterocycle; X is (un)substituted C1-4 alkylene; W and Z are each independently a bond or a C1-2 alkylene; Y and A are each independently (un)substituted Ph, (un)substituted pyridinyl, (un)substituted pyrimidinyl, (un)substituted pyrazinyl, etc.; B is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted pyridinyl, etc.; including tautomers, enantiomers, salts, and mixts. thereof, with 6 specific compds. excluded. The invention also relates to the preparation of I, pharmaceutical compns. containing I and one or more physiol. acceptable excipients, inert carriers or diluents, as well as to the use of the compns. for the treatment of metabolic disorders and/or eating disorders, particularly obesity and



diabetes. N-Alkylation of 3-methylpyridine with benzyl chloride followed by hydride reduction, asym. dihydroxylation, and debenzylation gave optically active piperidinediol II. 2-Bromoethanol underwent substitution with 4-iodo-2-methylphenol to give the corresponding ether, which was coupled with trimethylsilylacetylene and desilylated to give alkyne III. Coupling of III with 2,5-dibromopyridine, Suzuki coupling with 4-chlorophenylboronic acid, mesylation and substitution with piperidinediol II resulted in the formation of diarylalkyne IV. The compds. of the invention are MCH-receptor antagonists, with compound IV expressing an IC50 value of 10.9 nM.

IT 866928-10-1P, (3S,4R)-1-[2-[4-[[5-(4-Chlorophenyl)pyridin-2-yl]ethynyl]-2-(methyl)phenoxy]ethyl]-4-(trifluoromethyl)piperidine-3,4-diol 866928-11-2P 866928-37-2P, (3S,4R)-1-[2-[4-[[5-(4-Chlorophenyl)pyridin-2-ylethynyl]phenoxy]ethyl]-4-trifluoromethylpiperidine-3,4-diol 866928-39-4P 866928-69-0P, (3R,4S)-1-[2-[4-[[5-(4-Chlorophenyl)-3-fluoropyridin-2-ylethynyl]phenoxy]ethyl]-4-methylpiperidine-3,4-diol 866928-71-4P 866928-76-9P 866928-79-2P 868051-86-9P 868051-87-0P 868051-88-1P 868051-89-2P 868051-90-5P 868051-91-6P 868051-92-7P 868051-93-8P 868051-94-9P 868051-95-0P 868051-96-1P 868052-04-4P 868052-05-5P 868052-06-6P 868052-07-7P 868052-08-8P 868052-09-9P 868052-10-2P 868052-11-3P 868052-12-4P 868052-13-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diarylalkynes as MCH-receptor antagonists)

RN 866928-10-1 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866928-11-2 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/697,443

RN 866928-37-2 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866928-39-4 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866928-69-0 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866928-71-4 CAPLUS

CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/697,443



RN 866928-76-9 CAPLUS

CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866928-79-2 CAPLUS

CN Cyclopropanol, 1-[(2S)-1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/697,443




RN 868051-86-9 CAPLUS  
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl-, (3R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-87-0 CAPLUS  
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl-, (3S,4R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868051-88-1 CAPLUS  
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-methyl-, (3S,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/697,443



RN 868051-89-2 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868051-90-5 CAPLUS

CN 3,4-Pyrrolidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 868051-91-6 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/697,443

RN 868051-92-7 CAPLUS


CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-93-8 CAPLUS


CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 868051-94-9 CAPLUS

CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868051-95-0 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- $\alpha,\alpha$ -dimethyl-, (2S)- (9CI) (CA INDEX NAME)

10/697,443


Absolute stereochemistry.



RN 868051-96-1 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-hydroxy-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868052-04-4 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868052-05-5 CAPLUS

10/697,443

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868052-06-6 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-methyl-, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868052-07-7 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868052-08-8 CAPLUS

CN 3,4-Pyrrolidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/697,443




RN 868052-09-9 CAPLUS  
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868052-10-2 CAPLUS  
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868052-11-3 CAPLUS  
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 868052-12-4 CAPLUS  
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

10/697,443


Absolute stereochemistry.



RN 868052-13-5 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-α,α-dimethyl-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1146296 CAPLUS

DOCUMENT NUMBER: 143:430115

TITLE: Acetylene compound in smectic liquid crystal composition to improve various properties and liquid crystal display

INVENTOR(S): Ochi, Takahiko; Totani, Yoshiyuki

PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005298453	A	20051027	JP 2004-121155	20040416
PRIORITY APPLN. INFO.: GI			JP 2004-121155	20040416



AB The title acetylene compound is represented by a general formula I (A = pyridine-2,5-diyl; B, C = 1,4-phenylene, trans-1,4-cyclohexylene, 2,6-naphthylene; R1 = C2-24-alkyl, C2-4-alkoxyalkyl, C2-24-unsatd. hydrocarbyl; R2 = C2-24-alkoxyalkyl; X1, X3 = single bond, -C.tplbond.C-, -O-, -COO-, -OCO-; X2 = single bond, -COO-, -OCO-; Y1, Y2 = H, halo; n = 0, 1). 5 Synthetic examples, 5 liquid crystal mixture examples, and 5 liquid crystal display examples are given.

IT 868379-91-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of acetylene compound; acetylene compound in smectic liquid crystal

composition to improve various properties and liquid crystal display)

RN 868379-91-3 CAPLUS

CN Pyridine, 5-[[3-fluoro-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-2-(nonyloxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1132924 CAPLUS

DOCUMENT NUMBER: 143:405812

TITLE: Preparation of substituted pyridine alkynes with MCH antagonistic activity for the treatment of metabolic disorders

INVENTOR(S): Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald; Juergen; Rudolf, Klaus; Schindler, Marcus; Thomas, Leo; Lotz, Ralf

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: U.S. Pat. Appl. Publ., 67 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2005234101	A1	20051020	US 2005-104889	20050413
DE 102004017934	A1	20051103	DE 2004-102004017934	20040414
CA 2559688	A1	20051103	CA 2005-2559688	20050408
WO 2005103002	A2	20051103	WO 2005-EP3685	20050408
WO 2005103002	A3	20060202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1737823	A2	20070103	EP 2005-737015	20050408
------------	----	----------	----------------	----------

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: DE 2004-102004017934A 20040414  
US 2004-563590P P 20040420  
WO 2005-EP3685 W 20050408

GI



AB Various substituted pyridinyl alkynes are prepared For instance, 2-[[[4-[[5-(4-chlorophenyl)pyridin-2-yl]ethynyl]-2-methylphenyl]oxy]ethyl methanesulfonate (I) is prepared in 6 steps from 4-iodophenol, 2-bromoethanol, trimethylsilylacetylene, 2,5-dibromopyridine and 4-chlorophenylboronic acid. This intermediate is reacted with a variety of amines to produce example compds. I is converted to II by displacement with the corresponding amine. II exhibits an IC<sub>50</sub> = 6.2 nM for MCH-1. Example compds. are useful for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

IT 690265-45-3P 866929-02-4P 866929-03-5P  
866929-04-6P 866929-05-7P 866929-06-8P  
866929-16-0P 866929-19-3P 866929-27-3P  
866929-35-3P 866929-42-2P 866934-41-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyridine alkynes with MCH antagonistic activity for treatment of metabolic disorders)

10/697,443


RN 690265-45-3 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-02-4 CAPLUS


CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-03-5 CAPLUS


CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866929-04-6 CAPLUS


CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-05-7 CAPLUS


10/697,443

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(2,6-dimethyl-1-piperidinyloxy)]- (9CI) (CA INDEX NAME)




RN 866929-06-8 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(3,5-dimethyl-1-piperidinyloxy)]- (9CI) (CA INDEX NAME)




RN 866929-16-0 CAPLUS

CN Pyridine, 3-bromo-5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyloxy)]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 866929-19-3 CAPLUS

CN 3-Pyridinamine, 5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyloxy)]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-27-3 CAPLUS


CN Benzaldehyde, 4-[6-[[4-[2-(4-methyl-1-piperidinyloxy)]phenyl]ethynyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



10/697,443

RN 866929-35-3 CAPLUS


CN Phenol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-42-2 CAPLUS


CN Cyclohexanol, 4-methyl-1-[6-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-3-pyridinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866934-41-0 CAPLUS

CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 866928-04-3P 866928-05-4P 866928-06-5P  
866928-07-6P 866928-08-7P 866928-10-1P  
866928-11-2P 866928-14-5P 866928-15-6P  
866928-16-7P 866928-17-8P 866928-18-9P  
866928-29-2P 866928-31-6P 866928-32-7P  
866928-33-8P 866928-37-2P 866928-39-4P  
866928-41-8P 866928-43-0P 866928-45-2P  
866928-55-4P 866928-58-7P 866928-63-4P  
866928-64-5P 866928-65-6P 866928-66-7P  
866928-67-8P 866928-68-9P 866928-69-0P  
866928-70-3P 866928-71-4P 866928-72-5P  
866928-73-6P 866928-74-7P 866928-75-8P  
866928-76-9P 866928-77-0P 866928-78-1P  
866928-79-2P 866928-80-5P 866928-81-6P  
866928-82-7P 866928-83-8P 866928-88-3P  
866928-89-4P 866928-90-7P 866928-91-8P  
866928-92-9P 866928-93-0P 866928-94-1P  
866928-95-2P 866928-96-3P 866928-97-4P  
866928-98-5P 866928-99-6P 866929-00-2P

10/697,443

866929-01-3P 866929-07-9P 866929-08-0P  
866929-09-1P 866929-10-4P 866929-11-5P  
866929-12-6P 866929-13-7P 866929-14-8P  
866929-15-9P 866929-17-1P 866929-18-2P  
866929-21-7P 866929-22-8P 866929-23-9P  
866929-26-2P 866929-28-4P 866929-29-5P  
866929-31-9P 866929-32-0P 866929-33-1P  
866929-36-4P 866929-37-5P 866929-41-1P  
866929-43-3P 866929-45-5P 866929-46-6P  
866929-47-7P 866929-57-9P 866929-58-0P  
866931-04-6P 867029-81-0P 867029-82-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyridine alkynes with MCH antagonistic activity for treatment of metabolic disorders)

RN 866928-04-3 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866928-05-4 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866928-06-5 CAPLUS




10/697,443

CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 866928-07-6 CAPLUS

CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- $\alpha$ -(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-08-7 CAPLUS


CN Ethanone, 1-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-piperidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 866928-10-1 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866928-11-2 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-

10/697,443


methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-14-5 CAPLUS


CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 866928-15-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-methyl-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866928-16-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-ethyl-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866928-17-8 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-(trifluoromethyl)-, (3-exo)-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-18-9 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 866928-29-2 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/697,443




RN 866928-31-6 CAPLUS  
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-32-7 CAPLUS  
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- $\alpha$ -(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-33-8 CAPLUS  
CN Ethanone, 1-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-piperidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 866928-37-2 CAPLUS  
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA

10/697,443

INDEX NAME)


Absolute stereochemistry.



RN 866928-39-4 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866928-41-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-methyl-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866928-43-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-ethyl-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866928-45-2 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-(trifluoromethyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-55-4 CAPLUS


CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 866928-58-7 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)


10/697,443



RN 866928-63-4 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-64-5 CAPLUS

CN Pyridine, 2-[[4-[2-(1-azetidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 866928-65-6 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/697,443



RN 866928-66-7 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-67-8 CAPLUS

CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 866928-68-9 CAPLUS

CN 3-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




10/697,443




RN 866928-69-0 CAPLUS  
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866928-70-3 CAPLUS  
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-71-4 CAPLUS  
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/697,443



RN 866928-72-5 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866928-73-6 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/697,443



RN 866928-74-7 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[3-methyl-4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]-(9CI) (CA INDEX NAME)



RN 866928-75-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 866928-76-9 CAPLUS

CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/697,443



RN 866928-77-0 CAPLUS


CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 866928-78-1 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866928-79-2 CAPLUS

CN Cyclopropanol, 1-[(2S)-1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-

10/697,443

pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866928-80-5 CAPLUS

CN Pyridine, 2-[[3-bromo-4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 866928-81-6 CAPLUS


CN 4-Piperidinol, 1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

10/697,443



RN 866928-82-7 CAPLUS


CN Pyridine, 2-[[3-bromo-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (9CI) (CA INDEX NAME)



RN 866928-83-8 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-88-3 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethenyl-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



10/697,443

RN 866928-89-4 CAPLUS


CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-ethenylphenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866928-90-7 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-ethenylphenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-91-8 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4,4-dimethyl-1-piperidinyl)ethoxy]-3-ethenylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866928-92-9 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-(1-methylethenyl)-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)


10/697,443



RN 866928-93-0 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-(1-methylethenyl)phenoxy]ethyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-94-1 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-(1-methylethenyl)phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 866928-95-2 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4,4-dimethyl-1-piperidinyl)ethoxy]-3-(1-methylethenyl)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




10/697,443



RN 866928-96-3 CAPLUS


CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-(1-methylethenyl)phenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-97-4 CAPLUS

CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866928-98-5 CAPLUS


CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 866928-99-6 CAPLUS

CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4,4-dimethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 866929-00-2 CAPLUS

CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[4-hydroxy-4-(trifluoromethyl)-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 866929-01-3 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 866929-07-9 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

10/697,443




RN 866929-08-0 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-1-piperidinyloxy)]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 866929-09-1 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(2,6-dimethyl-1-piperidinyloxy)]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 866929-10-4 CAPLUS


CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(3,5-dimethyl-1-piperidinyloxy)]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 866929-11-5 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyloxy)]-, oxime (9CI) (CA INDEX NAME)


10/697,443



RN 866929-12-6 CAPLUS


CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 866929-13-7 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-1-piperidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)



RN 866929-14-8 CAPLUS


CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(2,6-dimethyl-1-piperidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)



RN 866929-15-9 CAPLUS


CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)

10/697,443




RN 866929-17-1 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-3-methyl-2-[[4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 866929-18-2 CAPLUS

CN Pyridine, 3-methyl-5-(4-methylphenyl)-2-[[4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-21-7 CAPLUS

CN Pyridine, 3-chloro-5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 866929-22-8 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[4-[[3-chloro-5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/697,443




RN 866929-23-9 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[3-chloro-5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866929-26-2 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-28-4 CAPLUS


CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-α-methyl-2-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

10/697,443




● HCl


RN 866929-29-5 CAPLUS  
CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-α-methyl-2-[2-(4-methyl-1-piperidinyloxy)]- (9CI) (CA INDEX NAME)



RN 866929-31-9 CAPLUS  
CN Pyridine, 5-[4-(difluoromethyl)phenyl]-2-[[4-[2-(4-methyl-1-piperidinyloxy)]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 866929-32-0 CAPLUS  
CN Benzenemethanamine, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 866929-33-1 CAPLUS  
CN Acetamide, N-[5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyloxy)]phenyl]ethynyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 866929-36-4 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-propoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-37-5 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-41-1 CAPLUS


CN Cyclohexanol, 4-methyl-1-[6-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-3-pyridinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866929-43-3 CAPLUS

CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]-α-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 866929-45-5 CAPLUS




10/697,443

CN 3-Pyridinamine, 5-(4-chlorophenyl)-N-methyl-2-[[4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 866929-46-6 CAPLUS

CN 3-Pyridinamine, 5-(4-chlorophenyl)-N,N-dimethyl-2-[[4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 866929-47-7 CAPLUS

CN Pyridine, 5-(4-methyl-1-cyclohexen-1-yl)-2-[[4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 866929-57-9 CAPLUS

CN Pyridine, 3-fluoro-5-(4-methyl-1-cyclohexen-1-yl)-2-[[4-[2-(4-methyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-58-0 CAPLUS


CN 4-Piperidinol, 1-[2-[4-[[3-fluoro-5-(4-methyl-1-cyclohexen-1-yl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



10/697,443

RN 866931-04-6 CAPLUS


CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]- $\alpha$ -methyl-2-[2-(1-pyrrolidinyloxy)- (9CI) (CA INDEX NAME)



RN 867029-81-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-(trifluoromethyl)-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 867029-82-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-(trifluoromethyl)-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 690265-82-8P, 5-Bromo-2-[(4-[2-(4-methylpiperidin-1-yl)ethoxy]phenyl)ethynyl]pyridine 866930-55-4P,  
5-(4-Chlorophenyl)-2-[(3-isopropoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)ethynyl]pyridine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of substituted pyridine alkynes with MCH antagonistic activity  
for treatment of metabolic disorders)  
RN 690265-82-8 CAPLUS  
CN Pyridine, 5-bromo-2-[(4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl)ethynyl]-  
(9CI) (CA INDEX NAME)



RN 866930-55-4 CAPLUS  
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-(1-methylethoxy)-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:1008939 CAPLUS  
DOCUMENT NUMBER: 143:471878  
TITLE: Synthesis of some oligopyridine-galactose conjugates  
and their metal complexes: a simple entry to  
multivalent sugar ligands  
AUTHOR(S): Orlandi, Simonetta; Annunziata, Rita; Benaglia,  
Maurizio; Cozzi, Franco; Manzoni, Leonardo  
CORPORATE SOURCE: Centro di Eccellenza CISI, Dipartimento di Chimica  
Organica e Industriale, Universita' degli Studi di  
Milano, Milan, 20133, Italy  
SOURCE: Tetrahedron (2005), 61(42), 10048-10060  
CODEN: TETRAB; ISSN: 0040-4020  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 143:471878  
AB Some galactose-oligopyridine conjugates were readily assembled by  
combining differently functionalized oligopyridines with peracetylated  
galactose derivs. Variation in the structure of the components and of the  
linkers employed for their connection afforded adducts of different size,  
shape, and conformational mobility. Complexation of the bipyridine  
ligands with CuOTf and of the terpyridine ligand with Zn(OTf)<sub>2</sub> afforded  
the corresponding peracetylated 2:1 and 1:1 complexes, resp., as single  
species. Their structures are tetrahedral (Cu complexes) and  
trigonal-bipyramidal (Zn complex), from spectroscopic evidence. Removal  
of the acetyl protecting groups from the ligands afforded the  
corresponding polyols. The terpyridine-Zn(II) complex, unlike the  
bipyridine-Cu(I) complexes maintained their structures upon removal of the  
acetyl protecting groups.

10/697,443

IT 868992-08-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(preparation of oligopyridine-galactose conjugates and their copper and zinc  
complexes)


RN 868992-08-9 CAPLUS

CN  $\beta$ -D-Galactopyranoside, [2,2'-bipyridine]-6,6'-diylbis(2,1-ethynediyl-  
4,1-phenylene) bis-, 2,2',3,3',4,4',6,6'-octaacetate (9CI) (CA INDEX  
NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A





IT 868992-11-4P 868992-13-6P 868992-16-9P



RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of oligopyridine-galactose conjugates and their copper and zinc complexes)

RN 868992-11-4 CAPLUS



CN  $\beta$ -D-Galactopyranose, [2,2':6',2''-terpyridine]-6,6''-diylbis(2,1-ethynediyl-4,1-phenylene) bis-, 2,2',3,3',4,4',6,6'-octaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 868992-13-6 CAPLUS  
 CN  $\beta$ -D-Galactopyranoside, [2,2'-bipyridine]-6,6'-diylbis(2,1-ethynediyl-4,1-phenylene) bis- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 868992-16-9 CAPLUS

CN  $\beta$ -D-Galactopyranoside, [2,2':6',2''-terpyridine]-6,6''-diylbis(2,1-ethynediyl-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:390227 CAPLUS

DOCUMENT NUMBER: 140:406742

TITLE: Preparation of ethynylpyridines and related compounds as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.

INVENTOR(S): Mueller, Stephan-Georg; Stenkamp, Dirk; Arndt, Kirsten; Roth, Gerald Juergen; Lotz, Ralf Richard Hermann; Lehmann-Lintz, Thorsten; Lenter, Martin; Lustenberger, Philipp; Rudolf, Klaus

PATENT ASSIGNEE(S): Boehringer Ingelheim, Germany



SOURCE: PCT Int. Appl., 361 pp.




CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039780	A1	20040513	WO 2003-EP11887	20031025
WO 2004039780	A8	20040715		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10250708	A1	20040519	DE 2002-10250708	20021031
CA 2504160	A1	20040513	CA 2003-2504160	20031025
AU 2003300507	A1	20040525	AU 2003-300507	20031025
EP 1558578	A1	20050803	EP 2003-809734	20031025
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014839	A	20050830	BR 2003-14839	20031025
CN 1732154	A	20060208	CN 2003-80102635	20031025
JP 2006511492	T	20060406	JP 2004-547566	20031025
US 2004209865	A1	20041021	US 2003-697443	20031030
NO 2005000749	A	20050523	NO 2005-749	20050211
PRIORITY APPLN. INFO.:			DE 2002-10250708	A 20021031
			US 2003-456543P	P 20030321
			WO 2003-EP11887	W 20031025
OTHER SOURCE(S):		MARPAT 140:406742		
GI				



II



III

AB Title compds. I [R<sub>1</sub>, R<sub>2</sub> = H, (un)substituted alkyl, cycloalkyl, etc; X = alkyl, alkenyl, alkynyl, etc.; W, Z = alkylene with provisos; Y = Cy with provisos; A = Cy; B = Cy, alkyl, alkenyl, etc.; Cy = (un)substituted carbocycle, heterocycle] and their pharmaceutically acceptable salts and formulations were prepared. For example, palladium mediated coupling of bromopyridine II, e.g., prepared from 4-iodophenol in 2-steps, and

4-bromophenylboronic acid afforded claimed ethynylpyridine III in 11% yield. In melanin concentrating hormone receptor (MCH-1R) binding assays, 2-examples of compds. I exhibited IC50 values ranging from 8-74 nM, e.g., the IC50 of ethynylpyridine III was 8 nM. Compds. I are claimed useful for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.


IT 690262-91-0P 690263-08-2P 690263-15-1P  
690263-20-8P 690263-78-6P 690265-45-3P  
690266-06-9P 690266-07-0P 690266-10-5P  
690266-42-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of ethynylpyridines and related compds. as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.)


RN 690262-91-0 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690263-08-2 CAPLUS

CN Pyridine, 2-[[3-bromo-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 690263-15-1 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-20-8 CAPLUS


CN Carbamic acid, [1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/697,443




RN 690263-78-6 CAPLUS

CN 4-Piperidinemethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 690265-45-3 CAPLUS

CN Benzaldehyde, 5-[[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690266-06-9 CAPLUS

CN Carbamic acid, [[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-piperidinyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B


—OBu-t

RN 690266-07-0 CAPLUS

CN Carbamic acid, [(3R)-1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— OBU-t

RN 690266-10-5 CAPLUS  
 CN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

— OBU-t

RN 690266-42-3 CAPLUS  
 CN Carbamic acid, [1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl-4-piperidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 690262-71-6P 690262-74-9P 690262-75-0P  
 690262-83-0P 690262-88-5P 690262-89-6P  
 690262-90-9P 690262-93-2P 690262-94-3P  
 690263-04-8P 690263-05-9P 690263-09-3P  
 690263-11-7P 690263-13-9P 690263-14-0P  
 690263-18-4P 690263-21-9P 690263-22-0P  
 690263-24-2P 690263-25-3P 690263-28-6P  
 690263-29-7P 690263-30-0P 690263-31-1P  
 690263-32-2P 690263-34-4P 690263-35-5P  
 690263-36-6P 690263-37-7P 690263-38-8P  
 690263-43-5P 690263-48-0P 690263-49-1P  
 690263-50-4P 690263-52-6P 690263-53-7P  
 690263-54-8P 690263-55-9P 690263-57-1P  
 690263-58-2P 690263-59-3P 690263-60-6P  
 690263-61-7P 690263-63-9P 690263-65-1P  
 690263-66-2P 690263-67-3P 690263-68-4P  
 690263-69-5P 690263-70-8P 690263-72-0P  
 690263-73-1P 690263-74-2P 690263-76-4P  
 690263-77-5P 690263-79-7P 690263-81-1P  
 690263-85-5P 690263-88-8P 690263-94-6P  
 690264-06-3P 690264-07-4P 690264-08-5P  
 690264-09-6P 690264-32-5P 690264-38-1P  
 690264-44-9P 690264-48-3P 690264-54-1P  
 690264-57-4P 690264-61-0P 690264-63-2P  
 690264-69-8P 690265-20-4P 690265-33-9P  
 690265-39-5P 690265-77-1P 690265-81-7P  
 690265-83-9P 690265-99-7P 690266-02-5P  
 690266-03-6P 690266-08-1P 690266-09-2P  
 690266-12-7P 690266-13-8P 690266-14-9P  
 690266-15-0P 690266-16-1P 690266-17-2P  
 690266-20-7P 690266-21-8P 690266-22-9P  
 690266-24-1P 690266-25-2P 690266-29-6P  
 690266-30-9P 690266-32-1P 690266-33-2P  
 690266-34-3P 690266-35-4P 690266-36-5P  
 690266-39-8P 690266-40-1P 690266-41-2P  
 690266-43-4P 690266-44-5P 690266-45-6P  
 690266-46-7P 690266-47-8P 690266-48-9P  
 690266-49-0P 690266-50-3P 690266-52-5P  
 690266-53-6P 690266-54-7P 690266-55-8P  
 690267-33-5P 690267-34-6P 690267-35-7P  
 690267-36-8P 690267-37-9P 690267-38-0P  
 690267-39-1P 690267-40-4P 690267-41-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of ethynylpyridines and related compds. as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.)

RN 690262-71-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/697,443




RN 690262-74-9 CAPLUS  
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690262-75-0 CAPLUS  
CN 3-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 690262-83-0 CAPLUS  
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-propyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690262-88-5 CAPLUS  
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,6-dimethyl-1-piperidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690262-89-6 CAPLUS

CN Benzoic acid, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 690262-90-9 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-(1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690262-93-2 CAPLUS


CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690262-94-3 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)


10/697,443



RN 690263-04-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690263-05-9 CAPLUS

CN Benzenamine, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 690263-09-3 CAPLUS

CN 1H-Azepine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-hexahydro- (9CI) (CA INDEX NAME)




10/697,443




RN 690263-11-7 CAPLUS

CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N-methyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 690263-13-9 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 690263-14-0 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690263-18-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


10/697,443




RN 690263-21-9 CAPLUS  
 CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690263-22-0 CAPLUS  
 CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-24-2 CAPLUS  
 CN Pyridine, 2-[[4-[2-(1-azetidinyloxy)phenyl]ethynyl]-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 690263-25-3 CAPLUS  
 CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 690263-28-6 CAPLUS  
 CN Pyridine, 5-(4-chlorophenyl)-2-[[3-chloro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

10/697,443


pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-29-7 CAPLUS


CN 3-Pyrrolidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 690263-30-0 CAPLUS

CN 2-Pyridinamine, N-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 690263-31-1 CAPLUS


CN Pyridine, 5-(4-bromophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-32-2 CAPLUS


CN Acetamide, N-[[[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-piperidinyl]methyl]-N-methyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690263-34-4 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-ethyl-1-piperidinyloxy)phenyl]ethynyl]-1-piperidinyloxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690263-35-5 CAPLUS

CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 690263-36-6 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-1-piperidinyloxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-37-7 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]phenyl]ethynyl]-1-piperidinyloxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-38-8 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2-methyl-1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-1-piperidinyloxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690263-43-5 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 690263-48-0 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[4-(2-pyridinyloxy)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-49-1 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690263-50-4 CAPLUS


CN 3-Pyrrolidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/697,443




RN 690263-52-6 CAPLUS  
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690263-53-7 CAPLUS  
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 690263-54-8 CAPLUS  
CN Pyridine, 2-[[4-(2-[4,4'-bipiperidin]-1-ylethoxy)phenyl]ethynyl]-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 690263-55-9 CAPLUS  
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethynyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690263-57-1 CAPLUS

CN 4-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 690263-58-2 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)




RN 690263-59-3 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,6-dimethyl-1-piperidinyloxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-60-6 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[4-(1H-imidazol-4-yl)-1-piperidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



10/697,443


RN 690263-61-7 CAPLUS

CN 2-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 690263-63-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 690263-65-1 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-66-2 CAPLUS

CN 4-Piperidineethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B


—NEt<sub>2</sub>

RN 690263-67-3 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,4,6-trimethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




10/697,443



RN 690263-68-4 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-69-5 CAPLUS


CN Isoquinoline, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690263-70-8 CAPLUS


CN 2,6-Diazaspiro[3.4]octane, 6-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 690263-72-0 CAPLUS


CN 3-Pyrrolidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

10/697,443




RN 690263-73-1 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-fluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690263-74-2 CAPLUS

CN 4-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N-cyclopentyl-N-methyl- (9CI) (CA INDEX NAME)



RN 690263-76-4 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[4-(1-pyrrolidinyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



10/697,443


RN 690263-77-5 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690263-79-7 CAPLUS

CN Piperazine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 690263-81-1 CAPLUS

CN Spiro[piperidine-4,2'-(1'H)-quinazolin]-4'-(3'H)-one, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 690263-85-5 CAPLUS

CN 3,9-Diazaspiro[5.5]undecane, 3-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-9-methyl- (9CI) (CA INDEX NAME)



RN 690263-88-8 CAPLUS

CN Isoquinoline, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




10/697,443

RN 690263-94-6 CAPLUS


CN Isoquinoline, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 690264-06-3 CAPLUS

CN Pyridine, 5-(4-fluorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690264-07-4 CAPLUS

CN Pyridine, 2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-5-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 690264-08-5 CAPLUS


CN Pyridine, 5-(4-methoxyphenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-09-6 CAPLUS


CN Pyridine, 2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690264-32-5 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3,5-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690264-38-1 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]-3-(trifluoromethoxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690264-44-9 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]-3-(trifluoromethyl)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-48-3 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[2-chloro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-54-1 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-nitro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690264-57-4 CAPLUS

CN Benzoic acid, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-3-methyl-2-[2-(1-pyrrolidinyl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 690264-61-0 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(1-ethyl-3-piperidinyl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-63-2 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690264-69-8 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690265-20-4 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[2-fluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl] - (9CI) (CA INDEX NAME)




RN 690265-33-9 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[1-methyl-2-(1-piperidinyloxy)phenyl]ethynyl] - (9CI) (CA INDEX NAME)



RN 690265-39-5 CAPLUS


CN Benzonitrile, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy] - (9CI) (CA INDEX NAME)



RN 690265-77-1 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-(2-pyridinyl)-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl] - (9CI) (CA INDEX NAME)

10/697,443




RN 690265-81-7 CAPLUS

CN Pyridine, 2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-5-phenyl-(9CI) (CA INDEX NAME)



RN 690265-83-9 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690265-99-7 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/697,443



RN 690266-02-5 CAPLUS


CN Morpholine, 4-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690266-03-6 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690266-08-1 CAPLUS


CN 2-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



10/697,443


RN 690266-09-2 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2-ethyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690266-12-7 CAPLUS

CN 2-Piperidineethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 690266-13-8 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-phenyl-1-piperidinyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690266-14-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 690266-15-0 CAPLUS

CN 4H-Thieno[2,3-d]azepine, 6-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 690266-16-1 CAPLUS

CN Quinoline, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)


10/697,443

decahydro- (9CI) (CA INDEX NAME)



RN 690266-17-2 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-20-7 CAPLUS


CN 3-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690266-21-8 CAPLUS


CN 4-Piperidinemethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



10/697,443


RN 690266-22-9 CAPLUS

CN 3-Pyrrolidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 690266-24-1 CAPLUS

CN Proline, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 690266-25-2 CAPLUS


CN 4-Piperidinemethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 690266-29-6 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-30-9 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[4-(1-methylethyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690266-32-1 CAPLUS

CN 1H-1,4-Diazepine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 690266-33-2 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[2-(1-methylethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-34-3 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[2-(phenylmethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-35-4 CAPLUS


CN 4-Piperidinone, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)

10/697,443




RN 690266-36-5 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,2-dimethyl-3-phenyl-1-pyrrolidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690266-39-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 690266-40-1 CAPLUS


CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,3-dimethyl-1-piperidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-41-2 CAPLUS


CN Piperazine, 1-acetyl-4-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)

10/697,443



RN 690266-43-4 CAPLUS


CN Methanesulfonamide, N-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 690266-44-5 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe

RN 690266-45-6 CAPLUS

CN 4-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 690266-46-7 CAPLUS

CN 1,2-Ethanediamine, N'-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-

10/697,443

methylphenoxy]ethyl]-4-piperidiny]-N,N-diethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>—NEt<sub>2</sub>


RN 690266-47-8 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine], 1'-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-1,2-dihydro-1-(methylsulfonyl)-(9CI) (CA INDEX NAME)



RN 690266-48-9 CAPLUS

CN 1H-Isoindole, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 690266-49-0 CAPLUS



10/697,443


CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 690266-50-3 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[4-(trifluoromethyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690266-52-5 CAPLUS

CN 4-Piperidinone, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, oxime (9CI) (CA INDEX NAME)



RN 690266-53-6 CAPLUS


CN 4-Piperidinone, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 690266-54-7 CAPLUS


10/697,443

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[3-(1-piperidinyl)-1-azetidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 690266-55-8 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 690267-33-5 CAPLUS

CN Benzoic acid, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 690267-34-6 CAPLUS

CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N,N-dimethyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)





RN 690267-35-7 CAPLUS

CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 690267-36-8 CAPLUS

CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N-cyclopropyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690267-37-9 CAPLUS

CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 690267-38-0 CAPLUS

CN Acetamide, N-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-


10/697,443

pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 690267-39-1 CAPLUS

Methanesulfonamide, N-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 690267-40-4 CAPLUS

Benzenamine, 5-[[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N,N-dimethyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690267-41-5 CAPLUS

CN Benzenamine, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N-methyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



IT 690264-05-2P 690265-82-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


```
(preparation of ethynylpyridines and related compds. as
```

melanin-concentrating

hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.)


RN 690264-05-2 CAPLUS

CN Pyridine, 5-bromo-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI)  
(CA INDEX NAME)



RN 690265-82-8 CAPLUS

CN Pyridine, 5-bromo-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-(9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:403795 CAPLUS

DOCUMENT NUMBER: 139:130257

TITLE: A europium chelate for quantitative point-of-care immunoassays using direct surface measurement

AUTHOR(S): von Lode, Piia; Rosenberg, Jaana; Pettersson, Kim; Takalo, Harri

CORPORATE SOURCE: Department of Biotechnology, University of Turku, Turku, FIN-20520, Finland

SOURCE: Analytical Chemistry (2003), 75(13), 3193-3201

CODEN: ANCHAM; ISSN: 0003-2700

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB New labels and assay techniques are needed to improve the sensitivity and quantitateness of point-of-care immunotesting while sustaining the rapidity and ease of use of the assays. We synthesized a novel, intrinsically fluorescent nonadentate europium chelate with two chromophores and hydrophilic  $\alpha$ -galactose side groups. The chelate is highly fluorescent, soluble in water, and provides effective shielding of Eu from water. The performance of the nonadentate chelate was compared with a heptadentate chelate in a dry reagent immunoassay for human chorionic gonadotropin (hCG). After 15-min incubation and washing, time-resolved fluorescence was measured directly from a wet or dried well surface. Contrary to the heptadentate label, the effect of aqueous quenching on the nonadentate label was found to be insignificant, with calculated anal. detection limits (background + 3 SD) of 0.9 and 0.7 IU/L hCG for wet and dry measurements, resp., and a linear range up to 5000 IU/L. The CVs for the new label were <8% at the cutoff of 25 IU/L and above in both whole blood and plasma. The novel nonadentate label facilitates short

10/697,443

turnaround times and simple instrumentation due to the absence of all signal development steps, at the same time retaining an excellent immunoassay performance.

IT 565230-36-6P 565230-37-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(europium chelate for quant. point-of-care immunoassays using direct surface measurement)

RN 565230-36-6 CAPLUS


CN Glycine, N,N'-[[[2-(4-aminophenyl)ethyl]imino]bis[methylene[4-[[4-  
[(2,3,4,6-tetra-O-acetyl- $\alpha$ -D-galactopyranosyl)oxy]phenyl]ethynyl]-  
6,2-pyridinediyl]methylene]]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-,  
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1996:694357 CAPLUS  
 DOCUMENT NUMBER: 125:317360  
 TITLE: Use of retinoids for the manufacture of a medicament for the treatment of restenosis  
 INVENTOR(S): Davies, Peter A. J.; Chandraratna, Roshantha A.; Benedict, Claude R.  
 PATENT ASSIGNEE(S): Allergan, USA; Board of Regents  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629069	A1	19960926	WO 1996-US3749	19960319
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2215731	A1	19960926	CA 1996-2215731	19960319
AU 9652565	A	19961008	AU 1996-52565	19960319
AU 712029	B2	19991028		
EP 814799	A1	19980107	EP 1996-908866	19960319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11509830	T	19990831	JP 1996-528571	19960319
US 5798372	A	19980825	US 1997-794289	19970203
PRIORITY APPLN. INFO.:			US 1995-407733	A 19950320
			WO 1996-US3749	W 19960319

GI





I


AB A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering a retinoid, such as an RAR-selective retinoid, e.g. I.

IT 176731-71-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(retinoids for treatment of restenosis)

RN 176731-71-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




IT 176731-70-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(retinoids for treatment of restenosis)

RN 176731-70-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:467291 CAPLUS

DOCUMENT NUMBER: 125:167797

TITLE: Preparation of [(tetrahydropyranyloxy)phenylethynyl]nicotines and analogs having retinoid-like biological activity

INVENTOR(S): Song, Tae K.; Chandraratna, Roshantha A.


PATENT ASSIGNEE(S): Allergan, USA

SOURCE: U.S., 15 pp.

DOCUMENT TYPE: CODEN: USXXAM  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5534641	A	19960709	US 1994-366173	19941229
WO 9620938	A1	19960711	WO 1995-US15805	19951207
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9644161	A	19960724	AU 1996-44161	19951207
US 5698700	A	19971216	US 1996-656128	19960531
US 5847160	A	19981208	US 1997-923720	19970904
PRIORITY APPLN. INFO.:			US 1994-366173	A 19941229
			WO 1995-US15805	W 19951207
			US 1996-656128	A3 19960531

GI



AB R1ZZ1C.tplbond.CZ2Z3R3 [R1 = 2-tetrahydropyranyl; R3 = H, CO2H, alkoxy carbonyl, CONH2, etc.; Z = O or S; Z1 = (un)substituted phenylene; Z2 = (un)substituted phenylene, -heteroarylene; Z3 = bond, (cyclo)alkylene, alkenylene, alkynylene] were prepared. Thus, 3-BrC6H4OH was alkylated with Me3COH and the 3,4-dihydro-2H-pyran etherified product alkynylated by HC.tplbond.CSiMe3 to give, after deprotection, 3,4-(R1O)(Me3C)C6H3C.tplbond.CH. The latter was arylated by Et 6-iodonicotinate to give title compound I which had IC80 of 0.56nmols (sic) against ornithine decarboxylase.


IT 176731-70-7P 176731-71-8P 176731-77-4P  
 176731-78-5P 180341-45-1P 180341-46-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(tetrahydropyranyloxy)phenylethynyl]nicotinate and analogs having retinoid-like biol. activity)

RN 176731-70-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 176731-71-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-


10/697,443

pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 176731-77-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylphenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 176731-78-5 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 180341-45-1 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/697,443



RN 180341-46-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:229119 CAPLUS

DOCUMENT NUMBER: 124:343128

TITLE: Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity

INVENTOR(S): Song, Tae K.; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: U.S., 16 pp.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5498795	A	19960312	US 1994-366170	19941229
WO 9620937	A1	19960711	WO 1995-US15804	19951207
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9644160	A	19960724	AU 1996-44160	19951207
PRIORITY APPLN. INFO.:			US 1994-366170	A 19941229
			WO 1995-US15804	W 19951207
OTHER SOURCE(S):		MARPAT 124:343128		
GI				



I



II

AB Compds. of the formula I wherein R1-R3 and R5 independently are H, lower alkyl of 1 to 6 carbons, branched chain alkyl or cycloalkyl of 3 to 15 carbons, lower alkyl substituted cycloalkyl of 3 to 15 carbons; R4 is lower alkyl of 1 to 6 carbons, branched chain alkyl or cycloalkyl of 3 to 15 carbons or lower alkyl substituted cycloalkyl of 3 to 15 carbons; X is S or O; Y is a Ph group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl and oxazolyl, said groups being substituted with the R5 group defined above; A is (CH<sub>2</sub>)<sub>n</sub> where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR8, CONR9R10, CH2OH, CH2OR11, CH2OCOR11, CHO, CH(OR12)2, CHOR13O, COR7, CR7(OR12)2, or CR7OR13O, where R7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R8 is Ph or lower alkylphenyl, R9 and R10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or Ph or lower alkylphenyl, R11 is lower alkyl, Ph or lower alkylphenyl, R12 is lower alkyl, and R13 is divalent alkyl radical of 2-5 carbons, have retinoid-like biol. activity. Thus, e.g., deblocking of Et 4-[2-[[2-t-butyl-1-(2-tetrahydropyranoxy)]-4-phenyl]ethyn-1-yl]benzoate (preparation given) with pyridinium p-toluenesulfonate afforded Et 4-[2-(2-t-butyl-1-hydroxy-4-phenyl)ethyn-1-yl]benzoate (II) which exhibited IC<sub>80</sub> = 0.89 nmol for inhibition of 12-O-tetradecanoylphorbol 13-acetate induction of ornithine decarboxylase activity.

IT 176731-70-7P 176731-71-8P 176731-77-4P  
176731-78-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biol. activity)

RN 176731-70-7 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/697,443




RN 176731-71-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 176731-77-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylphenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 176731-78-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:484524 CAPLUS

DOCUMENT NUMBER: 119:84524

TITLE: Luminescence of europium(III) chelates with 4-(arylethynyl)pyridines as ligands

AUTHOR(S): Takalo, Harri; Hanninen, Elina; Kankare, Jouko

CORPORATE SOURCE: Cent. Biotechnol., Turku, SF-20521, Finland

SOURCE: Helvetica Chimica Acta (1993), 76(2), 877-83

CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Some spectral properties and luminescence intensities of Eu(III) chelates with 15 4-(arylethynyl)pyridine-2,6-dicarboxylic acids and 11 2,2',2'',2'''-{[4-(arylethynyl)pyridine-2,6-diyl]bis(methylenenitrilo)}tetraakis(acetic acids) were measured both in H<sub>2</sub>O and EtOH solns. to develop suitable labels for time-resolved luminescence-based bioaffinity assays. Several of the latter ligands and their Eu complexes were prepared for the 1st time. The substitution at the aryl group has a significant effect upon the observed luminescence intensities, excitation wavelengths, and decay consts. of the complexes. Moreover, the changes in the environment cause great variation in those properties of certain Eu(III) chelates.

IT 148902-66-3D, europium complex

RL: PRP (Properties)  
(luminescence of)

RN 148902-66-3 CAPLUS

CN 2,6-Pyridinedicarboxylic acid, 4-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:154111 CAPLUS

DOCUMENT NUMBER: 110:154111

TITLE: Synthesis of some substituted dimethyl and diethyl 4-(phenylethynyl)-2,6-pyridinedicarboxylates

AUTHOR(S): Takalo, Harri; Kankare, Jouko; Hanninen, Elina

CORPORATE SOURCE: Dep. Chem., Univ. Turku, Turku, SF-20500, Finland

SOURCE: Acta Chemica Scandinavica, Series B: Organic

10/697,443

Chemistry and Biochemistry (1988), B42(7), 448-54  
CODEN: ACBOCV; ISSN: 0302-4369

DOCUMENT TYPE:

Journal


LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 110:154111

GI




AB 4-(Phenylethynyl)-2,6-pyridinedicarboxylates I (R = substituted Ph, R1 = Me, Et) were prepared by coupling reactions between dialkyl 4-halo-2,6-pyridinedicarboxylates and terminal arylacetylenes in the presence of an organopalladium catalyst and copper(I) iodide in a suitable solvent system. The terminal acetylenes were synthesized from the corresponding aryl halides using either (trimethylsilyl)acetylene or 2-methyl-3-butyn-2-ol followed by deprotection of the triple bond.

IT 119754-30-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 119754-30-2 CAPLUS

CN 2,6-Pyridinedicarboxylic acid, 4-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, dimethyl ester (9CI) (CA INDEX NAME)



=>